Wolfgang Kern
Ludwig Maximilian University of Munich
652 Papers
3.9K Citations
Wolfgang Kern is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 80, co-authored 585 publications. Previous affiliations of Wolfgang Kern include German Cancer Research Center & University of Münster.
Chat about Author
Papers
MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.
TL;DR: MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations and this finding has implications for treatments for multiple sclerosis and other types of cancer.
6
RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.
TL;DR: The aim of the present study was the evaluation and comparison of associated genetic alterations, prognosis, and presence of RUNX1 in the main clone in de novo AML, s-AML and MDS cases with RUNX2mut, as differences between the respective entities have not been analyzed to date.
6
Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients
Alexander Kohlmann,Vera Grossmann,Sonja Schindela,Wolfgang Kern,Claudia Haferlach,Torsten Haferlach,Susanne Schnittger +6 more
TL;DR: Investigation of next-generation amplicon deep-sequencing of RUNX1 mutations found dominant clones were proven to disappear during course of the disease and existing low-level or novel clones were emerging at s-AML stage, and the technique of ultra-deep sequencing would be superior to current routine testing methods during follow-up and in detecting MRD.
6
Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia.
TL;DR: A case is described with cytomorphologically and immunologically proven B-cell chronic lymphocytic leukemia in which t(14;18)(q32;q21) was found.
6
Monitoring of Minimal Residual Disease Using Next-Generation Deep-Sequencing in 460 Acute Myeloid Leukemia Cases identifies RUNX1 Mutated Patients with Resistant Disease
Alexander Kohlmann,Vera Grossmann,Stefan Harbich,Frank Dicker,Tamara Alpermann,Niroshan Nadarajah,Wolfgang Kern,Claudia Haferlach,Torsten Haferlach,Susanne Schnittger +9 more
TL;DR: RUNX1 mutations were proposed as clinically useful biomarkers to follow disease progression from MDS to s-AML, as well as to monitor minimal residual disease (MRD) and were applied to characterize an unselected prospectively collected cohort during the subsequent 12-months routine diagnostics period starting 07/2010.
6